A systems approach to enhance clinical research and medicines development
Journal Title: Journal of Medicines Development Sciences - Year 2015, Vol 1, Issue 1
Abstract
The biopharmaceutical industry has traditionally been the key link between basic biomedical discovery and novel medicines. Today, the industry faces numerous challenges including the broad agreement that the current clinical trial system is inefficient and flawed. Most challenges are worsened by the inability of the stakeholders to work collaboratively. Over the last decade, many cooperative efforts to transform clinical research have been launched, but a systemic solution has not been envisioned. A systems approach, including the application of systems engineering principles, has been used in other sectors and proposed for use in healthcare and medicines development. Clinical research, when looked at in systems terms, can be defined as an open system involving patients, investigators and associated staff, regulators, sponsors and stakeholders interconnected through a series of processes to bring effective and safe medicines into the market. ACRES is a global nonprofit organization with a mission of creating a multi-sector alliance of individuals and institutions collaborating on building a shared global system for clinical research excellence. A fundamental element of the ACRES system includes a global network of high-performing research sites interconnected through a shared information technology platform, with standardized policies and operational procedures and a robust, secure database to support performance, quality and safety. Five core initiatives address the larger mission and are currently ongoing. Deliverables will roll out over 2015–2018. Positive reception to the concept, vision and goals among critical stakeholders, and a steady influx of strategic allies willing to work collaboratively demonstrates the strong pull exerted by the vision of a global system. However, due to the undertakings’ scope and complexity, challenges remain. Recognition that effective shared collaboration is the best long-term option among stakeholders and the general public constitutes a powerful incentive for ACRES contributors and strategic allies to keep working and make it happen.
Authors and Affiliations
Honorio Silva, Greg Koski, Matthew Whalen, Mary Tobin, Beat Widler, Al O. Pacino II and Brian Edwards
Keywords
Related Articles
- EP ID EP679261
- DOI -
- Views 141
- Downloads 0
It pays to promote joint PhD programmes between academia and the private sector
The prosperity of a country is closely related to its level of education to fuel research and innovation. Doctoral graduates have attained the highest education level and should be the key players in research and innovat...
Competencies: A new currency for continuing professional development
“No research without trained researchers” has become the mantra of the EU-funded Innovative Medicines Initiative (IMI) education and training projects. However, it is often hard to determine the type of training required...
The Predictive Safety Testing Consortium: safety biomarkers, collaboration, and qualification
The Predictive Safety Testing Consortium (PSTC) is one of nine consortia comprising the Critical Path Institute (C-Path), a non-profit organisation launched in 2005 and dedicated to playing the role of a catalyst in the...
Critical Path to Tuberculosis Drug Regimens: Global collaboration to accelerate development of novel drug regimens and rapid drug susceptibility tests for tuberculosis
The Critical Path to Tuberculosis Drug Regimens (CPTR) initiative aims to support the rational deployment of new tuberculosis (TB) therapies by speeding the development and impact of new and markedly improved drug regime...
European initiatives for better training in medicines development
In the last decade, the environment for medicines development has undergone unprecedented change, including: a shift from predominantly big Pharma to one of extensive industry–academia and SME partnerships and collaborat...